
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc. is poised for a favorable market position due to the promising clinical data from its medicine candidate RLY-2608, which shows improved efficacy and tolerability profiles compared to the existing PI3Ka inhibitor, capivasertib. This enhancement is expected to drive rapid market uptake, potentially increasing the penetration of PI3Ka inhibitors and expanding the market for these therapies significantly. Given that capivasertib has already expanded the market to approximately $700 million, the advancements with RLY-2608 could lead to further substantial revenue opportunities for Relay Therapeutics.
Bears say
Relay Therapeutics Inc's stock outlook is negatively impacted by a significant reduction in the expected median progression-free survival (mPFS) for their product candidates, dropping approximately 80% from 24 months to just 5 months, which raises concerns regarding the efficacy of their therapies. Additionally, safety liabilities related to inavolisib’s inhibition of wt-PI3Ka—particularly in patients with metabolic unfitness—have led to a disappointing commercial launch, failing to meet expectations for a first-line treatment. Competitive pressures in the market, exemplified by declining sales for Piqray, further illustrate the challenging environment Relay Therapeutics faces as it seeks to establish its products in the precision oncology space.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares